Trial Condition(s):

Colorectal Neoplasms

Metastatic Colorectal cancer patients with Long-term response to regorafenib (COLONG)

Bayer Identifier:

19577

ClinicalTrials.gov Identifier:

NCT03386825

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic colorectal cancer(mCRC) patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017. In addition, this study aims to describe the clinical characteristics of Belgian patients with a short- or long-term DoT to Stivarga.

Inclusion Criteria
- Male or female patients ≥ 18 years of age. 
- Patients who suffer from mCRC and who started treatment with Stivarga between the 1st of July 2015 and 31 July 2017.
- Patients who already received alternative treatment options before Stivarga for the treatment of mCRC or who were not eligible for other treatment options.
- Eastern Cooperative Oncology Group performance status (ECOG PS)  ≤ 1 at start of Stivarga treatment.
- Sufficient kidney, liver and bone marrow function start of Stivarga treatment.
- Life expectancy ≥ 3 months at start of Stivarga treatment
Exclusion Criteria
- Patients participating in an investigational program/clinical trial with interventions outside of routine clinical practice during the observational period.

Trial Summary

Enrollment Goal
76
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Belgium

many locations, Belgium

Status
Completed
 

Trial Design